Reducing the Burden of Malaria by Targeting Hotspots of Malaria Transmission
NCT01575613 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 17506
Last updated 2012-11-27
Summary
In this study, the investigators propose to determine the value of rolling out four targeted malaria control efforts in reducing overall malaria transmission. These targeted control efforts include local upscaling of IRS and ITNs in hotspots of malaria transmission. In addition, larviciding will be employed to target malaria vectors, also those that are less susceptible to IRS and ITNs as a consequence of outdoor feeding and resting. Lastly, the human infectious reservoir will be reduced in hotspots of malaria transmission by treating parasite carriers and their household members with the current first-line antimalarial drug. The impact of these targeted interventions on overall transmission intensity will be assessed in the context of currently ongoing malaria control activities in a plausibility study. Hotspots of malaria transmission are defined in an area of 100km2 and randomized to receive hotspot targeted interventions and compared with their baseline and with control clusters where the routine (untargeted) malaria control activities continue. The interventions will be evaluated based on changes in parasite prevalence measured in community surveys inside and outside hotspots of malaria transmission. Parasite prevalence will be compared before and after the intervention in intervention clusters and between intervention and control clusters.
In addition to malaria surveys in the human population, an entomological evaluation will take place where the densities of mosquito larvae and adult mosquitoes are monitored longitudinally.
Conditions
Interventions
- DRUG
-
Artemether-lumefantrine combination
Focal screening and treatment in all households in malaria hotspots prior to the peak transmission season. Screening of a sentinel age group by rapid diagnostic tests; all parasitaemic individuals and household members of parasitaemic individuals will be treated.
- BIOLOGICAL
-
Bacillus thuringiensis
Treatment of all waterbodies within hotspots with Bti or Bs on weekly basis
- BIOLOGICAL
-
Long lasting insecticide treated net (LLINs)
Distribution of LLINs in all households in malaria hotspots; instruction about correct use.
- BIOLOGICAL
-
Indoor Residual Spraying (IRS)
6-monthly IRS with deltamethrin in all households malaria hotspots.
Sponsors & Collaborators
-
London School of Hygiene and Tropical Medicine
collaborator OTHER -
Kenya Medical Research Institute
collaborator OTHER -
Centers for Disease Control and Prevention
collaborator FED -
International Centre of Insect Physiology and Ecology (ICIPE)
collaborator OTHER -
Division of Malaria Control, Ministry of Health, Nairobi, Kenya
collaborator UNKNOWN -
Radboud University Medical Center
lead OTHER
Principal Investigators
-
Teun Bousema, PhD · Radboud University Medical Center
-
Jon Cox, PhD · London School of Hygiene and Tropical Medicine
-
Jennifer Stevenson, PhD · London School of Hygiene and Tropical Medicine
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 6 Months
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2012-04-30
- Primary Completion
- 2012-11-30
- Completion
- 2012-11-30
Countries
- Kenya
More Related Trials
-
Evaluating ATSBs for Malaria Reduction in Kenya
NCT05219565 ·Status: COMPLETED ·Phase: NA
-
Treatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy 2 (TRANSACT2)
NCT01939886 ·Status: COMPLETED ·Phase: PHASE3
-
Spatial Repellents for the Prevention of Malaria in Kenya
NCT04766879 ·Status: COMPLETED ·Phase: NA
-
Feasibility, Acceptability and Costs of a Multiple First-lines Artemisinin-based Combination Therapies
NCT04265573 ·Status: COMPLETED
-
Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso
NCT04695197 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine in Cameroon
NCT05340153 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy and Effectiveness of Combined Therapy for Uncomplicated Malaria Treatment in Peru
NCT00164216 ·Status: COMPLETED
-
Malaria Therapeutic Efficacy Study (TES) Kenya
NCT04767191 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Sulphadoxine-pyrimethamine and Artemisinin-containing Combination Therapy for Malaria
NCT00140361 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study
NCT02511353 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Amodiaquine-artesunate in Children Aged 6-59 Months With Uncomplicated P. Falciparum Malaria
NCT00425763 ·Status: COMPLETED ·Phase: PHASE4
-
Impact of Insecticide Resistance on Vector Control
NCT01713517 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy of Artemether-lumefantrine, Artesunate-amodiaquine and Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Malawi
NCT01326754 ·Status: COMPLETED ·Phase: NA
-
Ivermectin-artemisinin Combination Therapy for Eradication of Malaria
NCT05605925 ·Status: UNKNOWN ·Phase: PHASE4
-
Impact of Scaling up Mass Testing, Treatment and Tracking on Malaria Prevalence Among Children
NCT04167566 ·Status: COMPLETED ·Phase: NA
-
Therapeutic Efficacy Study of AL and DP in Western Kenya
NCT05060198 ·Status: COMPLETED ·Phase: NA
-
Research on the Economics of Artemisinin Combination Therapy (ACTs) for the Treatment of Malaria
NCT01350752 ·Status: COMPLETED ·Phase: NA
-
Reducing Malaria Transmission in Forest-going Mobile and Migrant Populations in Myanmar
NCT05025761 ·Status: UNKNOWN ·Phase: NA
-
Safety and Efficacy of Recommended Antimalarial in the Democratic Republic of the Congo
NCT04618523 ·Status: COMPLETED ·Phase: PHASE4
-
Targeted Chemo-elimination (TCE) of Malaria
NCT01872702 ·Status: COMPLETED ·Phase: NA
-
Malaria High-Risk Populations in Namibia
NCT04094727 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria.
NCT02089841 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Targeted Mass Drug Administration for Malaria in Ethiopia
NCT04241705 ·Status: UNKNOWN ·Phase: NA
-
Randomised Efficacy Study of Two Artemether-Lumefantrine Oral Formulations for the Treatment of Uncomplicated P. Falciparum Malaria
NCT00529867 ·Status: COMPLETED ·Phase: PHASE4
-
Mass-Drug Administration to Reduce Malaria Transmission
NCT00509015 ·Status: COMPLETED ·Phase: NA